IL15 and COVID-19: More studies with a larger population are necessary to evaluate combinations of increasing doses of IL-15 with other immunomodulatory agents such as immune checkpoint inhibitors or monoclonal antibodies targeting the infected cells to help restore and enhance the antiviral response during critical forms of COVID-19.